← Oncology Approval Tracker

FDA DECISION ·

Opdivo Qvantig

nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb

FDA approvalNew or expanded indicationColorectal cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

As subcutaneous monotherapy for adults with unresectable or metastatic MSI-high or mismatch repair-deficient colorectal cancer following intravenous nivolumab plus ipilimumab.

LAMPGEN ANALYSIS

Why it matters

The label provides a subcutaneous continuation option after the intravenous dual checkpoint regimen.

What research teams should watch

Set a clear handoff from IV combination therapy to subcutaneous monotherapy and retain the molecular testing record.

PRIMARY RECORDS

Sources